(Q46675487)

24 December 2017

title

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour (English)

1 reference

24 December 2017

1 reference

Florian Grimpen

1

1 reference

24 December 2017

Desmond Yip

2

1 reference

24 December 2017

Grant McArthur

3

1 reference

24 December 2017

Paul Waring

4

1 reference

24 December 2017

David Goldstein

5

1 reference

24 December 2017

Maurice Loughrey

6

1 reference

24 December 2017

Victoria Beshay

7

1 reference

24 December 2017

Guan Chong

8

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

Lancet Oncology Commission

published in

1 reference

24 December 2017

volume

6

1 reference

24 December 2017

page(s)

724-727

1 reference

24 December 2017

issue

9

1 reference

24 December 2017

Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

KIT mutations are common in testicular seminomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970321-1

7 January 2021

10.1016/S1470-2045(05)70321-1

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16129374

1 reference

24 December 2017